Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CHDI, Lundbeck collaborate for Huntington’s disease therapy research
As part of the partnership, CHDI will conduct pre-clinical studies on a Lundbeck investigative compound to determine the compound’s effect on P2X receptors that may be involved in
As part of the partnership, CHDI will conduct pre-clinical studies on a Lundbeck investigative compound to determine the compound’s effect on P2X receptors that may be involved in
The companies plan to invest $50m in the expansion project following the World Health Organization (WHO) approval, reports AllAfrica. The plant, which currently manufactures six million tablets per
The recruitment of half of target patient population triggered a €10m milestone payment from Ipsen to Active Biotech. Ipsen chairman and chief executive officer Marc de Garidel said
The hiPS-HEP, with homogeneity, a long life span of stable CYP activity and reproducibility, provides a range of in vitro applications such as drug discovery, toxicity testing and
Amitiza is a chloride channel activator indicated for the treatment of chronic idiopathic constipation (CIC) in adults and for IBS-C in women aged 18 years and old. In
The product is a generic version of Warner Chilcott Company’s Lo Loestrin Fe, indicated for use by women to prevent pregnancy. Warner Chilcott filed suit against Watson in
The octreotide formulations incorporate Aegis’ Intravail/ProTek excipients suitable for all routes of administration including oral, buccal, metered nasal spray, or injection. The Intravail/ProTek excipients allow for non-invasive delivery
The company has started distribution of the generic version of GlaxoSmithKline’s Requip XL. Actavis CEO Doug Boothe said, "The launch of Ropinirole Extended-Release Tablets showcases Actavis’ commitment in
The Met inhibitor ARQ 197 plus Erlotinib vs Erlotinib plus placebo in NSCLC (MARQUEE) trial began enrollment in January 2011 and is being conducted under a Special Protocol
Pertzye is indicated for the treatment of Exocrine Pancreatic Insufficiency (EPI) due to cystic fibrosis (CF) or other conditions. DCI marketed Pertzye formulation for over a decade under